3,452,576 Shares in Savara Inc. $SVRA Bought by Spruce Street Capital LP

Spruce Street Capital LP bought a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,452,576 shares of the company's stock, valued at approximately $21,267,868. Savara accounts for approximately 0.0% of Spruce Street Capital LP's holdings, making the stock its 8th largest position. Spruce Street Capital LP owned about 1.68% of Savara at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in SVRA. Mirae Asset Global Investments Co. Ltd. raised its holdings in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company's stock valued at $60,000 after acquiring an additional 3,205 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Savara in the 1st quarter valued at approximately $57,000. Russell Investments Group Ltd. grew its stake in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock worth $37,000 after acquiring an additional 9,463 shares during the period. Xponance LLC purchased a new position in shares of Savara in the fourth quarter worth $66,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Savara during the third quarter valued at approximately $44,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $10.14.

Savara Stock Performance

Shares of Savara stock traded down $0.20 on Friday, reaching $5.29. 753,505 shares of the company traded hands, compared to its average volume of 1,622,243. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. Savara Inc. has a 52 week low of $3.19 and a 52 week high of $7.01. The firm has a market capitalization of $1.09 billion, a PE ratio of -9.12 and a beta of 0.29. The company has a 50 day moving average of $5.71 and a 200 day moving average of $5.48.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities analysts forecast that Savara Inc. will post -0.62 earnings per share for the current year.

Savara Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.